A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab (FCFD4514S) in Patients With Geographic Atrophy Who Have Completed Genentech-Sponsored Lampalizumab Studies

Trial Profile

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab (FCFD4514S) in Patients With Geographic Atrophy Who Have Completed Genentech-Sponsored Lampalizumab Studies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Lampalizumab (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 13 Sep 2017 Planned End Date changed from 30 Jun 2019 to 28 Mar 2022.
    • 13 Sep 2017 Planned primary completion date changed from 30 Jun 2019 to 29 Jun 2019.
    • 02 May 2017 Planned number of patients changed from 100 to 113.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top